Treating early in the disease course: lessons from the CML model

gan Yilmaz, Musa, Jabbour, Elias
Cyhoeddwyd yn Semin Oncol (2015)

Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies

gan Jabbour, Elias, Kantarjian, Hagop
Cyhoeddwyd yn Blood Adv (2016)

A “NOVA ECONOMIA DO PROJETAMENTO” NO COMBATE À COVID-19 E AS CAPACIDADES ESTATAIS CHINESAS COMO FORÇA POLÍTICA ESTRATÉGICA // THE “NEW PROJECTMENT ECONOMY” IN THE FIGHT AGAINST COV...

gan Jabbour, Elias, Rodrigues, Bernardo Salgado
Cyhoeddwyd 2021

A “NOVA ECONOMIA DO PROJETAMENTO” NO COMBATE À COVID-19 E AS CAPACIDADES ESTATAIS CHINESAS COMO FORÇA POLÍTICA ESTRATÉGICA // THE “NEW PROJECTMENT ECONOMY” IN THE FIGHT AGAINST COV...

gan Jabbour, Elias, Rodrigues, Bernardo Salgado
Cyhoeddwyd 2021

A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

gan Jabbour, Elias, Lipton, Jeffrey H.
Cyhoeddwyd yn Clin Lymphoma Myeloma Leuk (2013)

A CHINA E A “SOCIALIZAÇÃO DO INVESTIMENTO”: UMA ABORDAGEM KEYNES-GERSCHENKRON-RANGEL-HIRSCHMAN

gan Jabbour, Elias, de Paula, Luiz Fernando
Cyhoeddwyd 2018

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

gan Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Cyhoeddwyd 2010

A CHINA E A “SOCIALIZAÇÃO DO INVESTIMENTO”: UMA ABORDAGEM KEYNES-GERSCHENKRON-RANGEL-HIRSCHMAN

gan Jabbour, Elias, de Paula, Luiz Fernando
Cyhoeddwyd 2018

Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A Review of Tyrosine Kinase Inhibitors

gan Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Cyhoeddwyd yn Cancer (2010)

The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

gan Yilmaz, Musa, Richard, Samantha, Jabbour, Elias
Cyhoeddwyd yn Ther Adv Hematol (2015)

Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm

gan Jabbour, Elias, Kantarjian, Hagop, Cortes, Jorge
Cyhoeddwyd yn Clin Lymphoma Myeloma Leuk (2015)

Selecting the Best Frontline Treatment in Chronic Myeloid Leukemia

gan Yilmaz, Musa, Abaza, Yasmin, Jabbour, Elias
Cyhoeddwyd yn Curr Hematol Malig Rep (2015)

FAILURE OF HYPOMETHYLATING AGENT-BASED THERAPY IN MYELODYSPLASTIC SYNDROMES

gan Kadia, Tapan M., Jabbour, Elias, Kantarjian, Hagop
Cyhoeddwyd 2011

Sustained Virologic Response After 6 Weeks of Therapy With a First-Generation Hepatitis C Virus Protease Inhibitor

gan Kyvernitakis, Andreas, Jabbour, Elias, Torres, Harrys A.
Cyhoeddwyd 2014

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation

gan Chew, Serena, Mackey, Melissa C., Jabbour, Elias
Cyhoeddwyd yn Ther Adv Hematol (2020)

Sudden Cardiopulmonary Collapse in a Patient With Coronavirus Disease 2019

gan Jabbour, Elias, Malik, Danish, Shiloh, Ariel L.
Cyhoeddwyd yn Chest (2021)

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

gan Jabbour, Elias, Cortes, Jorge E., Kantarjian, Hagop M.
Cyhoeddwyd 2009

Development and targeted use of nilotinib in chronic myeloid leukemia

gan Fava, Carmen, Kantarjian, Hagop, Cortes, Jorge, Jabbour, Elias
Cyhoeddwyd 2009

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

gan Jabbour, Elias, Saglio, Giuseppe, Radich, Jerald, Kantarjian, Hagop
Cyhoeddwyd yn Clin Lymphoma Myeloma Leuk (2012)

Thrombocytopenia in patients with myelodysplastic syndromes

gan Bryan, Jeffrey, Jabbour, Elias, Prescott, Hillary, Kantarjian, Hagop
Cyhoeddwyd yn Semin Hematol (2010)